ABIVAX Société Anonyme (NASDAQ:ABVX) Short Interest Update

ABIVAX Société Anonyme (NASDAQ:ABVX) was the target of a significant increase in short interest during the month of December. As of December 15th, there was short interest totalling 577,200 shares, an increase of 19.0% from the November 30th total of 484,900 shares. Based on an average daily volume of 139,700 shares, the short-interest ratio is presently 4.1 days. Currently, 1.1% of the company’s shares are sold short.

Wall Street Analyst Weigh In

A number of research firms have recently commented on ABVX. JMP Securities started coverage on ABIVAX Société Anonyme in a research note on Wednesday, December 4th. They set an “outperform” rating and a $33.00 target price on the stock. Citizens Jmp upgraded ABIVAX Société Anonyme to a “strong-buy” rating in a report on Wednesday, December 4th. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $38.67.

Institutional Investors Weigh In On ABIVAX Société Anonyme

Hedge funds have recently made changes to their positions in the company. BNP Paribas Financial Markets increased its stake in shares of ABIVAX Société Anonyme by 82.6% during the third quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company’s stock valued at $150,000 after buying an additional 5,900 shares during the period. Walleye Capital LLC increased its position in ABIVAX Société Anonyme by 45.8% during the 3rd quarter. Walleye Capital LLC now owns 257,417 shares of the company’s stock valued at $2,965,000 after purchasing an additional 80,807 shares during the period. Point72 Asset Management L.P. raised its holdings in shares of ABIVAX Société Anonyme by 28.2% in the 3rd quarter. Point72 Asset Management L.P. now owns 542,900 shares of the company’s stock valued at $6,254,000 after purchasing an additional 119,300 shares in the last quarter. Finally, abrdn plc lifted its position in shares of ABIVAX Société Anonyme by 167.7% in the 3rd quarter. abrdn plc now owns 316,431 shares of the company’s stock worth $3,645,000 after purchasing an additional 198,225 shares during the period. 47.91% of the stock is currently owned by hedge funds and other institutional investors.

ABIVAX Société Anonyme Trading Down 1.0 %

Shares of NASDAQ ABVX opened at $7.05 on Tuesday. ABIVAX Société Anonyme has a 52-week low of $6.65 and a 52-week high of $17.02. The stock has a 50 day moving average price of $9.06 and a 200 day moving average price of $10.88.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.